Kahn Brothers Group Portfolio Adjustments: Q4 2025 Activity Analysis
Kahn Brothers Group maintained its focus on Financial Services and Healthcare sectors in Q4 2025, with minor share adjustments across key holdings.
Thomas Graham, representing the investment arm Kahn Brothers Group, managed a substantial portfolio valued at approximately $564.7 million as of December 31, 2025. This quarter's activity primarily involved minor adjustments to existing positions, with no new positions initiated or any positions fully exited, according to the disclosed data.
The portfolio's allocation remains heavily concentrated in the Financial Services sector, which accounted for 18.11% of the total value, led by Citigroup Inc (C). Healthcare is the second-largest sector, comprising 19.55% (12.94% from Bayer AG Spons ADR (BAYRY) and 8.02% from Merck & Co. Inc. (MRK)).
Several holdings saw reductions in their share count during the quarter:
- Citigroup Inc (C): Experienced a negligible decrease of 0.04% in allocation.
- Bayer AG Spons ADR (BAYRY): Suffered a moderate decrease of 0.49% in allocation.
- Flagstar Financial, Inc. (NYCB): Saw a significant reduction of 2.78% in allocation.
- BP PLC (BP): Experienced a notable decrease of 4.35% in allocation.
- Seaboard Corp (SEB): Faced a substantial decrease of 5.68% in allocation.
Conversely, a few holdings showed increases:
- Organon & Co (OGN): Registered a slight increase of 0.35% in allocation.
- Alphabet Inc Class C (GOOG): Showed a modest increase of 0.52% in allocation.
Holdings like Merck & Co. Inc. (MRK), Walt Disney (DIS), and Idt Corp Class B (IDT) also saw minor reductions, but their overall impact on the portfolio was less pronounced compared to the larger holdings.
For a more detailed view of Kahn Brothers Group's investment strategy and holdings, visit their profile at https://www.insiderset.com/investor/thomas-graham-kahn-brothers-group. Detailed information on each stock can be found at https://www.insiderset.com/investors/stocks/